One tertiary endpoint of the trial investigates the impact of tofacitinib treatment on levels of autoantibodies and markers employed to diagnose AITD [e.g., anti-TPO, anti-TG, anti-thyroid stimulating hormone receptor (TSHR)] and celiac disease [e.g., anti-tissue transglutaminase (tTG), anti-deamidated gliadin peptide (DGP)]. The gene discussed is TG; the disease is celiac disease.